Lonafarnib (Zokinvy)
- Status:
- Do Not Prescribe (DNP)
- Decision Date:
- October 2022
Comments
DNP:
- Identification of prostate-specific membrane antigen-positive lesions by
positron emission tomography in adults with prostate cancer, after
radiolabelling with gallium-68
- Treatment of patients aged ≥12 months with a genetically confirmed
diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient
progeroid laminopathy associated with either a heterozygous LMNA mutation with
progerin-like protein accumulation or a homozygous or compound heterozygous
ZMPSTE24 mutation. (Decision date - November 2022)
search again